Ming-Jin Yang, Shu-Liang Guo, Don D Sin
European Respiratory Journal 2022; DOI: 10.1183/13993003.02332-2022
Extract
We thank Drs. Almagro and Martinez-Camblor for their interest in our work and for their salient comments. While we agree that there is no universally accepted definition of MACE (major adverse cardiovascular events), the US Food and Drug Administration (FDA) and the European Medicines Agency include nonfatal myocardial infarction and stroke as well as cardiovascular (CV) mortality in their MACE definition [1]. Importantly, this definition includes both hemorrhagic and ischemic stroke [1–4]. In our study, we followed this classical “3-point” definition of MACE (including hemorrhagic strokes). While this definition has been by far the most commonly used one in clinical trials and other studies for evaluation of CV therapeutics and interventions, we agree with Drs. Almagrao and Martinez-Camblor that there remains significant debate in the community on the merits of this definition with others proffering alternate definitions of MACE [1].
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: DDS has received honoraria for speaking engagements from GSK, AstraZeneca and Boehringer Ingelheim.
Conflict of interest: The other authors declare no conflicts of interest.
- Received December 5, 2022.
- Accepted December 12, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org
